Abstract：
No injection treatment has been proven to be effective in wrist osteoarthritis. When conservative measures fail, its management involves invasive surgery. Emergence of biotherapies based on adipose derived stem cells (ADSC) offers promising treatments for chondral degenerative diseases. Microfat (MF) and platelets-rich plasma (PRP) mixture, rich in growth factors and ADSC could be a minimally invasive injectable option in the treatment of wrist osteoarthritis. The aim of this uncontrolled prospective study was to evaluate the safety of a 4 mL autologous MF-PRP intra-articular injection, performed under local anesthesia. The secondary purpose was to describe the clinical and MRI results at 12 months of follow-up. Patients\' data collected were: occurrence of adverse effects, Visual analog scale (VAS), Disabilities of the Arm, Shoulder and Hand score (DASH) and Patient-Rated Wrist Evaluation (PRWE) scores, wrist strength, wrist range of motion and 5-level satisfaction scale. No serious adverse event was recorded. A statistically significant decrease in pain, DASH, PRWE and force was observed at each follow-up. Our preliminary results suggest that intra-articular autologous MF and PRP injection may be a new therapeutic strategy for wrist osteoarthritis resistant to medical symptomatic treatment prior to surgical interventions.
摘要：
没有注射治疗已被证明是有效的腕关节骨关节炎。当保守措施失败时，它的管理涉及侵入性手术。基于脂肪干细胞（ADSC）的生物疗法的出现为软骨退行性疾病提供了有希望的治疗方法。微脂（MF）和富含血小板的血浆（PRP）混合物，富含生长因子和ADSC可能是治疗腕关节骨性关节炎的微创注射选择。这项不受控制的前瞻性研究的目的是评估4mL自体MF-PRP关节内注射的安全性。在局部麻醉下进行。次要目的是描述随访12个月时的临床和MRI结果。收集的患者数据是：不良反应的发生，视觉模拟量表(VAS),手臂的残疾，肩手评分（DASH）和患者评分腕部评估（PRWE）评分，手腕力量,手腕活动范围和5级满意度量表。没有严重不良事件记录。疼痛有统计学意义的下降，DASH,在每次随访中观察PRWE和力量。我们的初步结果表明，关节内自体MF和PRP注射可能是腕关节骨关节炎的一种新的治疗策略，可在手术干预前抵抗医学对症治疗。
